ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended March 31, 2011, and provided highlights of recent key developments.
“HGS continues to have a strong cash position to fund the global commercial launch and further development of BENLYSTA, as well as investment in other areas of our product pipeline”
“With the approval and U.S. launch of BENLYSTA for the treatment of systemic lupus, HGS has achieved its goal of becoming a fully commercial biopharmaceutical company,” said H. Thomas Watkins, President and Chief Executive Officer. “BENLYSTA will be the most important driver of our growth over the next several years.”
